Andy Kidd, Aptinyx CEO

‘The place­bo caught up’: Months af­ter di­a­bet­ic nerve pain fail, Aptinyx sees an­oth­er pain tri­al fall through

In 2019, Aptinyx’s stock cratered af­ter it re­port­ed that its lead can­di­date failed a di­a­bet­ic nerve pain tri­al. Af­ter some ‘fur­ther analy­sis,’ the biotech re-upped with that same non-opi­oid pain drug in two more mid-stage stud­ies — an­oth­er di­a­bet­ic nerve pain tri­al and lat­er a fi­bromyal­gia tri­al.

In April, Aptinyx re­port­ed that its sec­ond di­a­bet­ic nerve pain tri­al al­so fell through. How­ev­er, the Illi­nois-based pen­ny stock biotech had one more shot for its NM­DA-mod­u­lat­ing drug, dubbed NYX-2925, in fi­bromyal­gia.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters